awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38839151-08B2B36E-0AF7-431B-BFF3-CA2EE49A7A66
Q38839151-08B2B36E-0AF7-431B-BFF3-CA2EE49A7A66
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38839151-08B2B36E-0AF7-431B-BFF3-CA2EE49A7A66
A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
P2860
Q38839151-08B2B36E-0AF7-431B-BFF3-CA2EE49A7A66
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38839151-08B2B36E-0AF7-431B-BFF3-CA2EE49A7A66
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c3d8e49c7be0c174b364b9c562465ab8ade400b8
P2860
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.